Daily Archives: February 5, 2021

During the recent COVID-19 pandemic, telemedicine has enabled many IBD patients worldwide to get access to remote assistance. Some positive reports on the use of telemedicine among patients and healthcare providers have been published1-4, but a patient… Continue reading →

Adolescents and young adults (AYA) with Inflammatory Bowel Disease (IBD) are at increased risk for poor psychological and physical well-being. Self-compassion (i.e., understanding and acceptance towards oneself) has been associated with better psycholo… Continue reading →

Rates of newly diagnosed inflammatory bowel disease (IBD) in pediatric patients increased by 133% from 2007–2016. With the rise comes an increase in patients ultimately transitioning from pediatric to adult GI care. While pediatric care is family-cente… Continue reading →

Serotonin affects intestinal physiology, mood, as well as circadian rhythm. Moreover, serotonin has proinflammatory function. Therefore, the aim of this study was to investigate the role of serotonin in clinical severity of Crohn’s Disease (CD) and its… Continue reading →

Gut-directed hypnosis (GDH) is a complimentary therapy for Inflammatory Bowel Disease (IBD), that can be learnt by patients to practice self-hypnosis. GDH in IBD has augmented remission and improved inflammation. GDH has a history of successful use for… Continue reading →

25% of children hospitalized with acute severe ulcerative colitis (ASUC) rescued with infliximab (IFX) at labeled dosing undergo a colectomy prior to discharge. Our aim was to determine whether IFX pharmacokinetics (PK) are associated with treatment re… Continue reading →

The emotional health of patients with IBD has been difficult to elucidate in routine IBD care, but is critical to medication adoption, adherence and self-management. Patients often are unsure how to communicate their preferences and concerns to their p… Continue reading →

The etiology of inflammatory bowel disease (IBD) is unknown. However, chronic inflammation from T cell activation and its subsequent tissue damage is implicated in the pathogenesis of IBD. Vedolizumab (VDZ), a monoclonal antibody against α4β7 integrin … Continue reading →

The clinical practice guideline for Crohn’s disease (CD) management strongly recommends the avoidance and cessation of smoking. However, no standardized smoking cessation (SC) program exists for CD patients. Results from a nationwide survey among U.S. … Continue reading →

A fast ( Continue reading →